Levine Arnold J
Institute for Advanced Study, Simons Center for Systems Biology, Princeton, USA.
J Clin Oncol Res. 2020;8(1). Epub 2020 Sep 22.
Tissue-specific stem cells are the target for selected mutations in oncogenes or tumor suppressor genes that enhance the fitness of these cells, resulting in a self-limited clonal expansion and eventual cancer development. The initial or truncal mutations in the stem cell select for subsequent mutations that enhance their fitness, producing a reproducible order of mutations, selected for in each tissue type, during cancer development. Mutations in stem cells occur randomly, but the selection for increased fitness, occurs non-randomly, conferring a functional order on the selection of mutations. Tissue-specific stem cells are "units of natural selection" for somatic stem cells throughout life. This is why inherited cancer-causing mutations, which, by definition, are initial or truncal mutations, are observed to cause cancers with limited tissue specificities, even though the mutations are present in stem cells for all tissue types. In future studies, we need to understand why the same signal transduction pathways function differently in different tissue-specific stem cells. We also need to understand the truncal mutations for each cancer type, so as to eradicate the stem cell clones for that cancer before they produce a malignant tumor. To accomplish these objectives, we need to carry out new kinds of clinical trials with drugs that target mutations in tissue-specific stem cells.
组织特异性干细胞是癌基因或肿瘤抑制基因中特定突变的靶点,这些突变增强了这些细胞的适应性,导致自我限制的克隆性扩增并最终引发癌症。干细胞中的初始或主干突变会选择后续增强其适应性的突变,在癌症发展过程中产生一种可重复的突变顺序,这种顺序在每种组织类型中都会被选择。干细胞中的突变是随机发生的,但对适应性增强的选择是非随机的,赋予了突变选择一种功能顺序。组织特异性干细胞在一生中都是体细胞干细胞的“自然选择单位”。这就是为什么遗传性致癌突变,根据定义是初始或主干突变,尽管这些突变存在于所有组织类型的干细胞中,但却被观察到会引发具有有限组织特异性的癌症。在未来的研究中,我们需要了解为什么相同的信号转导通路在不同的组织特异性干细胞中功能不同。我们还需要了解每种癌症类型的主干突变,以便在干细胞克隆产生恶性肿瘤之前根除该癌症的干细胞克隆。为了实现这些目标,我们需要开展针对组织特异性干细胞突变的新型药物临床试验。